Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 2 months later Dec 2026 → Mar 2028
See other at-risk trials from NKGen Biotech, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Dec 2026 to Mar 2028 Show 4 more changesShow less
    • Study completion pushed from Jun 2027 to Jun 2028
    • Eligibility criteria expanded, about 37 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised at 1 of 8 sites
  2. Site details revised at 1 of 8 sitesv11
  3. Site details revised at 2 of 8 sitesv10
  4. Primary completion date: Dec 2025 to Dec 2026
    • Study sites: 5 to 8
    • Study completion date: Jun 2026 to Jun 2027
    v9
  5. Site details revised at 1 of 5 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Site contacts updated at 1 of 5 sitesv7
  2. Study sites: 3 to 5v6
  3. Primary completion date: Dec 2024 to Dec 2025
    • Study completion date: Jun 2025 to Jun 2026
    • Site contacts updated at 1 of 3 sites
    v5
  4. Study sites: 1 to 3v4
  5. Secondary endpoints revised (2)v3
  6. Study title shortened, about 1 wordv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
NKGen Biotech, Inc.
2 trials monitored
See 1 trial at risk
Dementia
1,982 trials monitored
See 105 trials at risk
Alzheimer's Disease
1,255 trials monitored
See 68 trials at risk
The goal of this clinical trial is to test SNK01 in participants with moderate Alzheimer's Disease. The main questions it aims to answer are: 1. Is SNK01 safe and tolerable when administered every 3 weeks for up to 1 year as an intravenous infusion 2. Can SNK01 administration improve cognitive assessment scores and biomarkers
Trial Details
NCT Number NCT06189963
Lead Sponsor NKGen Biotech, Inc.
Conditions
(from sponsor)		 Moderate Alzheimer Disease
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov